IL259153A - Use of proteasome inhibitors to treat ocular disorders - Google Patents

Use of proteasome inhibitors to treat ocular disorders

Info

Publication number
IL259153A
IL259153A IL259153A IL25915318A IL259153A IL 259153 A IL259153 A IL 259153A IL 259153 A IL259153 A IL 259153A IL 25915318 A IL25915318 A IL 25915318A IL 259153 A IL259153 A IL 259153A
Authority
IL
Israel
Prior art keywords
proteasome inhibitors
ocular disorders
treat ocular
treat
disorders
Prior art date
Application number
IL259153A
Other languages
English (en)
Hebrew (he)
Original Assignee
Accuitis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accuitis Pharmaceuticals Inc filed Critical Accuitis Pharmaceuticals Inc
Publication of IL259153A publication Critical patent/IL259153A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL259153A 2015-11-06 2018-05-06 Use of proteasome inhibitors to treat ocular disorders IL259153A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562251937P 2015-11-06 2015-11-06
PCT/US2016/058402 WO2017078953A1 (en) 2015-11-06 2016-10-24 Use of proteasome inhibitors to treat ocular disorders

Publications (1)

Publication Number Publication Date
IL259153A true IL259153A (en) 2018-06-28

Family

ID=58662653

Family Applications (1)

Application Number Title Priority Date Filing Date
IL259153A IL259153A (en) 2015-11-06 2018-05-06 Use of proteasome inhibitors to treat ocular disorders

Country Status (8)

Country Link
US (1) US20180325854A1 (enExample)
EP (1) EP3370709A4 (enExample)
JP (1) JP2018533629A (enExample)
CN (1) CN108883081A (enExample)
AU (1) AU2016349833A1 (enExample)
CA (1) CA3004587A1 (enExample)
IL (1) IL259153A (enExample)
WO (1) WO2017078953A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11478499B2 (en) 2018-01-30 2022-10-25 Universiteit Gent Compositions for use to treat cataract
US11278493B2 (en) * 2018-12-10 2022-03-22 EternaTear, Inc. Ophthalmic formulations providing durable ocular lubrication
CN110840860B (zh) * 2019-11-22 2021-12-31 国家纳米科学中心 一种纳米药物及其制备方法和应用
US20230050398A1 (en) * 2021-08-04 2023-02-16 Harrow Ip, Llc Methods for increasing shelf-life of ophthalmic pharmaceutical compositions
US11471475B1 (en) 2022-03-08 2022-10-18 Ralph P. Stone Ophthalmic suspension vehicles and related methods for pharmaceutical ingredient delivery
US11679078B1 (en) 2022-03-08 2023-06-20 EternaTear, Inc. Ophthalmic formulations and related methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770115A (en) * 1996-04-19 1998-06-23 Ppg Industries, Inc. Photochromic naphthopyran compositions of improved fatigue resistance
ID26033A (id) * 1998-04-02 2000-11-16 Novartis Ag Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
SG157365A1 (en) * 2004-12-03 2009-12-29 Dana Farber Cancer Inst Inc Compositions and methods for treating neoplastic diseases
CA2609213C (en) * 2005-05-20 2016-08-23 Jack Arbiser Use of cinnamates to inhibit proteasome activity
AU2006308040A1 (en) * 2005-10-24 2007-05-03 Basf Se Protection of oxidizable agents
RU2456990C2 (ru) * 2006-09-15 2012-07-27 Янссен Фармацевтика Нв Комбинации специфичных ингибиторов гистоновых деацетилаз класса i с ингибиторами протеасом
CA2664790C (en) * 2006-09-29 2015-11-24 Johnson & Johnson Vision Care, Inc. Methods and ophthalmic devices used in the treatment of ocular allergies
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
CN103566049B (zh) * 2012-08-08 2017-08-04 浙江医药股份有限公司新昌制药厂 用于提高眼睛中视黄斑色素密度并预防或治疗年龄相关性视黄斑衰退症的组合物

Also Published As

Publication number Publication date
AU2016349833A1 (en) 2018-05-24
CN108883081A (zh) 2018-11-23
EP3370709A1 (en) 2018-09-12
JP2018533629A (ja) 2018-11-15
US20180325854A1 (en) 2018-11-15
EP3370709A4 (en) 2019-12-18
WO2017078953A1 (en) 2017-05-11
CA3004587A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
IL253244A0 (en) Methods for treating retinal diseases
IL251066B (en) Preparations and methods for the treatment of metabolic disorders
IL249793B (en) Preparations and methods of use for the treatment of metabolic disorders
GB201701673D0 (en) Methods of well treatment
HUE071728T2 (hu) Proliferációs betegségek kezelése Hedgehog útvonal inhibitorokat alkalmazva
ZA201700183B (en) Acetylcholinesterase inhibitors for treatment of dermatological conditions
IL259153A (en) Use of proteasome inhibitors to treat ocular disorders
IL258593B (en) Compounds for the treatment of subculture disorders
SG11201608397UA (en) Glyt1 inhibitors for use in the treatment of hematological disorders
IL251769A0 (en) Methods for treating eye conditions
GB201412578D0 (en) Treatment of neurological diseases
GB201416832D0 (en) Methods of treatment
GB201607388D0 (en) Treatment of impulsivity-related disorders
SG10201802808SA (en) Method of treating ocular disorders
EP3200795A4 (en) Use of agents for treating fat-related disorders
IL253231B (en) Use of bgp15 to treat familial dysautonomia
GB201421812D0 (en) New therapeutic uses of enzyme inhibitors
GB201410529D0 (en) New therapeutic uses of enzyme inhibitors
GB201602784D0 (en) New treatment of CFTR-related disorders
GB201521541D0 (en) New therapeutic uses of enzyme inhibitors
GB201521547D0 (en) New therapeutic uses of enzyme inhibitors